Carlos Rodriguez-Fierro, MD
Cardiovascular Disease · Marrero, LANPI 1740289727
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Medtronic at 41.3% of the total.
Across 341 payments — averaging $37.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Johnson & Johnson$923
- E.r. Squibb & Sons, L.L.C.$728
- Amgen$695
- Novartis$651
- Merck$390
- plus $4K from 29 others
What the payments were for
- Travel & lodging$1,1599%
- Food & beverage$11,58191%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 43 | $5,277 |
| Johnson & Johnson | 32 | $923 |
| E.r. Squibb & Sons, L.L.C. | 23 | $728 |
| Amgen | 27 | $695 |
| Novartis | 52 | $651 |
| Merck | 23 | $390 |
| Sanofi-aventis U.S. LLC | 13 | $348 |
| Pfizer | 8 | $314 |
| Esperion Therapeutics, Inc. | 12 | $288 |
| Alnylam Pharmaceuticals Inc. | 5 | $270 |
| Boehringer Ingelheim | 16 | $265 |
| AstraZeneca | 11 | $250 |
| Regeneron Healthcare Solutions, Inc. | 6 | $227 |
| Abbott | 5 | $215 |
| Boston Scientific | 9 | $199 |
| Amarin Pharma, Inc. | 8 | $191 |
| Inspire Medical Systems, Inc. | 1 | $167 |
| Impulse Dynamics (USA) Inc. | 2 | $144 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $133 |
| Biotronik Inc. | 1 | $130 |
| Edwards Lifesciences | 3 | $115 |
| Novo Nordisk | 5 | $114 |
| Chiesi USA, Inc. | 1 | $102 |
| Lilly USA, LLC | 1 | $95 |
| Arbor Pharmaceuticals, Inc. | 5 | $70 |
| Baxter Healthcare | 2 | $68 |
| Scpharmaceuticals Inc. | 3 | $65 |
| Bayer | 4 | $64 |
| Kowa Pharmaceuticals America, Inc. | 4 | $63 |
| Atricure, Inc. | 2 | $58 |
| Kestra Medical Technology Services, Inc. | 1 | $44 |
| Astellas Pharma US Inc | 2 | $37 |
| Philips North America LLC | 2 | $36 |
| Abiomed | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,267
- AZURE XT DR MRI SURESCAN$480
- LINQ II$456
- Resolute$403
- XARELTO$355
- COBALT DR MRI SURESCAN$303
- Claria MRI$293
- Evera$286
- ELIQUIS$273
- OPTIMIZER$246
- Repatha$242
- HawkOne$196
- Inspire Upper Airway Stimulation System$167
- CareLink$152
- CARDIOMEMS$142
- Reveal LINQ$126
- ONPATTRO$125
- PRALUENT$125
- CAMZYOS$125
- Vascepa$123
How this compares
$12,775 in reported general payments places this provider in the 80th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 641 | $548,383 |
| Repatha SureclickEvolocumab | 361 | $303,476 |
| EntrestoSacubitril/Valsartan | 218 | $228,184 |
| XareltoRivaroxaban | 196 | $182,762 |
| Praluent PenAlirocumab | 110 | $79,060 |
| NexletolBempedoic Acid | 73 | $45,267 |
| VascepaIcosapent Ethyl | 88 | $43,351 |
| JardianceEmpagliflozin | 46 | $33,957 |
| Repatha SyringeEvolocumab | 31 | $22,586 |
| Ranolazine ErRanolazine | 249 | $17,977 |
| VerquvoVericiguat | 25 | $17,110 |
| NexlizetBempedoic Acid/Ezetimibe | 36 | $15,150 |
| Metoprolol Succinate | 961 | $9,767 |
| Rosuvastatin Calcium | 874 | $8,336 |
| LivaloPitavastatin Calcium | 17 | $8,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $314 | $548,383641 claims |
| NovartisEntresto | $651 | $228,184218 claims |
| Johnson & JohnsonXarelto | $923 | $182,762196 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $288 | $60,417109 claims |
| Boehringer IngelheimJardiance | $265 | $33,95746 claims |
| MerckVerquvo | $390 | $17,11025 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $70 | $11,87135 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $63 | $8,10917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Marrero
- Frederick KushnerMarrero$62K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
- Darrell SoletMorgan City$81K
- Ghiath MikdadiHammond$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.